Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BLUE 
Bluebird bio Inc (BLUE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/30/2025: BLUE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $8
Year Target Price $8
| 0 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.18% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 05/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.67M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) - | Beta 0.36 | 52 Weeks Range 3.20 - 28.60 | Updated Date 06/29/2025 |
52 Weeks Range 3.20 - 28.60 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -20.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -192.39% | Operating Margin (TTM) -55.56% |
Management Effectiveness
Return on Assets (TTM) -28.37% | Return on Equity (TTM) -546.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 158068516 | Price to Sales(TTM) 0.47 |
Enterprise Value 158068516 | Price to Sales(TTM) 0.47 | ||
Enterprise Value to Revenue 1.52 | Enterprise Value to EBITDA -1.5 | Shares Outstanding 9792460 | Shares Floating 9725967 |
Shares Outstanding 9792460 | Shares Floating 9725967 | ||
Percent Insiders 0.71 | Percent Institutions 39.68 |
Analyst Ratings
Rating 3.25 | Target Price 8 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bluebird bio Inc
Company Overview
History and Background
Bluebird bio, Inc. was founded in 1992. Initially focused on gene therapy for genetic diseases, it has evolved through various clinical and regulatory hurdles. It has focused on severe genetic diseases and cancer.
Core Business Areas
- Severe Genetic Diseases: Bluebird bio develops gene therapies for severe genetic diseases, including sickle cell disease and beta-thalassemia. Focus is on one-time potentially curative gene therapies.
- Oncology: Focusing on the development of gene therapies in oncology, with focus on hematologic malignancies.
Leadership and Structure
Andrew Obenshain is the CEO. The company has a typical biotech structure with R&D, clinical development, manufacturing, and commercial operations departments.
Top Products and Market Share
Key Offerings
- Zynteglo (betibeglogene autotemcel): A gene therapy approved for beta-thalassemia. Competitors include traditional blood transfusions and iron chelation therapies. Limited market share data available due to newness and pricing challenges. Novartis is a major competitor in gene therapy.
- Skysona (elivaldogene autotemcel): A gene therapy approved for cerebral adrenoleukodystrophy (CALD). Competitors are allogeneic hematopoietic stem cell transplant (allo-HSCT). Limited market share data due to the rarity of the disease and treatment.
- Lyfgenia (lovotibeglogene autotemcel): A gene therapy approved for sickle cell disease. Competitors include hydroxyurea and chronic blood transfusions.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by technological advancements and increasing investment. High costs and regulatory complexities remain significant challenges.
Positioning
Bluebird bio is positioned as a pioneer in gene therapy, but faces competition from larger pharmaceutical companies and other specialized biotech firms.
Total Addressable Market (TAM)
The overall gene therapy market is expected to reach billions of dollars. Bluebird bio's success is contingent on gaining significant share within its targeted disease areas, especially with Zynteglo, Skysona, and Lyfgenia.
Upturn SWOT Analysis
Strengths
- Pioneering gene therapy platform
- Approved gene therapies for rare diseases
- Strong scientific expertise
- Focus on severe genetic diseases with high unmet need
Weaknesses
- High cost of therapies
- Regulatory challenges
- Manufacturing complexities
- Limited commercial success to date
- Cash burn rate
Opportunities
- Expanding indications for existing therapies
- Developing new gene therapies for other diseases
- Strategic partnerships with larger pharmaceutical companies
- Improved manufacturing processes to reduce costs
Threats
- Competition from other gene therapy companies
- Regulatory setbacks
- Reimbursement challenges
- Clinical trial failures
- Safety concerns with gene therapies
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- NTLA
- SRPT
- BMY
- NVS
Competitive Landscape
Bluebird bio has a first-mover advantage in some areas but faces strong competition from larger pharmaceutical companies and other gene therapy specialists. Its high prices pose a disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent due to clinical and regulatory challenges.
Future Projections: Future growth depends on successful commercialization of approved therapies, pipeline progress, and access to funding. Analyst estimates vary widely.
Recent Initiatives: Focus on commercializing approved therapies, cost reduction measures, and pipeline development.
Summary
Bluebird bio is a pioneering gene therapy company facing significant challenges in commercializing its expensive therapies. It has obtained key approvals for Zynteglo, Lyfgenia, and Skysona, but needs to overcome cost hurdles and competition to achieve sustainable growth. Financial stability and pipeline development remain crucial for its long-term success. The company must navigate a complex regulatory landscape while addressing reimbursement concerns to fully realize the potential of its gene therapy platform.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News
- Company Website
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market share data is estimated and may not be precise. Please conduct your own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bluebird bio Inc
Exchange NASDAQ | Headquaters Somerville, MA, United States | ||
IPO Launch date 2013-06-19 | President, CEO & Director Mr. Andrew Obenshain | ||
Sector Healthcare | Industry Biotechnology | Full time employees 248 | Website https://www.bluebirdbio.com |
Full time employees 248 | Website https://www.bluebirdbio.com | ||
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. As of May 29, 2025, bluebird bio, Inc. was taken private.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.